The IL-33/ST2 pathway to modulate the inflammatory microenvironment: A new therapeutic target in chronic obstructive pulmonary disease Authors: Xiaoyan Xie, Lei Yang, Jie Chen, Yonghong Wu, Jingjing Zhong, Hao Shen, Gaofeng Zheng Published: 2026 ABSTRACT The IL-33/ST2 pathway is critically implicated in the pathogenesis and progression of chronic obstructive pulmonary disease (COPD), orchestrating a complex interplay of oxidative stress, immunity, inflammation, and pulmonary injury. Clinical evidence shows that the expression levels of IL-33 and ST2 are significantly elevated in patients with COPD, which correlates strongly with disease severity, increased frequency of acute exacerbations, and negative clinical outcomes. Therapeutic strategies targeting the IL-33/ST2 pathway, including anti-IL-33 monoclonal antibodies and ST2 inhibitors, have demonstrated considerable potential in preclinical studies. These approaches have shown efficacy in mitigating inflammatory responses, enhancing lung function, and reducing the risk of acute exacerbations. Notably, the precise regulatory mechanisms of the IL-33/ST2 pathway in COPD and its crosstalk with inflammation remain incompletely understood and warrant further investigation. This review mainly elaborates the molecular biological characteristics and mechanism of IL-33/ST2, summarizes the function of IL-33/ST2 in COPD development and treatment, illustrates the application of IL-33/ST2 in patient's immune-inflammatory regulation and drug discovery, and discusses the prospects of targeting IL-33/ST2. Introduction In recent years, chronic obstructive pulmonary disease (COPD) has become one of the top three leading causes of global mortality, driven by rising disease exposure risks and an increasingly aging population [1,2]. The pathogenesis of COPD is underpinned by several hypotheses, including oxidative stress, protease/antiprotease imbalance, and chronic inflammation [3]. Importantly, immune mechanisms are intricately linked to these three hypotheses and have emerged as a focal point in contemporary COPD research, offering critical insights into the pathogenesis and progression of the disease [4]. Studies have confirmed that inflammatory responses cause lung tissue damage through various mechanisms, exposing self-tissue components of the body [5,6]. Acting as autoantigens, these components are recognized by autoreactive T cells, leading to T cell activation and proliferation. This process further enhances Macrophage and neutrophil mediated inflammation, facilitating the release of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) and chemokines (e.g., IL-8, MCP-1) [7]. These mediators continuously recruit immune cells to inflammatory loci, forming a vicious cycle between lung injury and disease progression. Thus, clarifying the molecular regulatory mechanisms of the immune-inflammatory microenvironment in COPD is of great significance for the development of targeted therapeutic strategies and the improvement of clinical prognosis in patients. It is well-established that IL-33 plays a crucial role in airway inflammation related to COPD. It signals through the ST2 receptor expressed on immune cells, thereby modulating immune and inflammatory responses [8]. Emerging evidence suggests that targeting the IL-33/ST2 axis holds considerable therapeutic potential for COPD, with ongoing clinical trials evaluating the safety and efficacy of novel biologics in this context [9]. This review summarizes the role of the IL-33/ST2 signaling pathway in COPD and explores the potential of targeted inhibitors, offering valuable insights for advancing clinical management and drug development in COPD. IL-33/ST2 pathway The gene encoding IL-33, which is located on chromosome 9, has an IL-1-like cytokine domain at its C-terminus, a nuclear localization domain at its N-terminus, and a protease-sensing domain in its central region [10]. Upon cellular damage or necrotic death, cells synthesizing IL-33 discharge the full-length IL-33 protein (IL-33FL). This protein can be proteolytically processed in the extracellular milieu by proteases derived from inflammatory cells, including neutrophils and mast cells, yielding a mature form of IL-33 with a potency 10 to 30 times greater than its precursor [11]. In the context of programmed cell death, known as apoptosis, IL-33 remains confined within the nucleus. Its translocation into the cytoplasm, mediated by caspase-3 and caspase-7, results in the inactivation of IL-33 [12] (Fig. 1, Fig. 2).Fig. 1Release of IL-33 and the IL-33/ST2 pathway. Full-length IL-33 (IL-33FL), a nuclear-localized cytokine, is a 270-amino acid protein predominantly stored in the nucleus. Its central protease-sensing domain contains key cleavage sites for inflammatory proteases (e.g., Neutrophil Elastase, Cathepsin G, Mast Cell Tryptase), enabling its processing by extracellular proteases into the hyperactive mature form of IL-33. However, during apoptosis, Caspases 3/7 inactivate IL-33 by cleaving the Asp 178 site. Upon exposure to allergens, physical damage, infections, or inflammatory stimuli, IL-33 is released from the nucleus into the extracellular space, where it activates cells expressing the ST2 receptor. As a member of the IL-1 receptor family, ST2 exists in two isoforms: a membrane-bound form (ST2L) and a soluble form (sST 2). IL-33 predominantly binds to membrane-bound ST2L and requires the IL-1 receptor accessory protein (IL-1RAcP) to form a complex. This interaction promotes the association of the TIR domain of ST2L with myeloid differentiation primary response protein 88 (MyD88), thereby initiating downstream signaling cascades.Fig. 2Role of the IL-33/ST2 pathway in the immune-inflammatory microenvironment of COPD. ST2, the specific receptor for IL-33, is expressed in various cell types, including T cells, Group 2 innate lymphoid cells, Tregs, Dendritic cells (DCs), Natural killer (NK) cells and Macrophages. When external stimuli affect COPD patients, they cause damage to the airway epithelium, leading to the release of the alarmin IL-33. By binding to its receptor ST2, IL-33 promotes interactions among immune cells and triggers the release of various pro-inflammatory cytokines, including IL-4, IL-5, IL-8, IL-12, IL-13, TNF-α, and INF-γ. This amplifies the immune-inflammatory response in COPD, resulting in increased airway inflammation, tissue remodeling, and lung damage. Release of IL-33 and the IL-33/ST2 pathway. Full-length IL-33 (IL-33FL), a nuclear-localized cytokine, is a 270-amino acid protein predominantly stored in the nucleus. Its central protease-sensing domain contains key cleavage sites for inflammatory proteases (e.g., Neutrophil Elastase, Cathepsin G, Mast Cell Tryptase), enabling its processing by extracellular proteases into the hyperactive mature form of IL-33. However, during apoptosis, Caspases 3/7 inactivate IL-33 by cleaving the Asp 178 site. Upon exposure to allergens, physical damage, infections, or inflammatory stimuli, IL-33 is released from the nucleus into the extracellular space, where it activates cells expressing the ST2 receptor. As a member of the IL-1 receptor family, ST2 exists in two isoforms: a membrane-bound form (ST2L) and a soluble form (sST 2). IL-33 predominantly binds to membrane-bound ST2L and requires the IL-1 receptor accessory protein (IL-1RAcP) to form a complex. This interaction promotes the association of the TIR domain of ST2L with myeloid differentiation primary response protein 88 (MyD88), thereby initiating downstream signaling cascades. Role of the IL-33/ST2 pathway in the immune-inflammatory microenvironment of COPD. ST2, the specific receptor for IL-33, is expressed in various cell types, including T cells, Group 2 innate lymphoid cells, Tregs, Dendritic cells (DCs), Natural killer (NK) cells and Macrophages. When external stimuli affect COPD patients, they cause damage to the airway epithelium, leading to the release of the alarmin IL-33. By binding to its receptor ST2, IL-33 promotes interactions among immune cells and triggers the release of various pro-inflammatory cytokines, including IL-4, IL-5, IL-8, IL-12, IL-13, TNF-α, and INF-γ. This amplifies the immune-inflammatory response in COPD, resulting in increased airway inflammation, tissue remodeling, and lung damage. As the most recently identified member of the IL-1 family, IL-33 is predominantly expressed in endothelial cells and epithelial cells of barrier tissues [13]. Under conditions of tissue or cell injury, IL-33 is released and exerts its effects by targeting a diverse array of inflammatory and immune cells, including mast cells, Macrophages, and eosinophils, among others [[14], [15], [16]]. Due to its role in signaling tissue damage and initiating immune responses, IL-33 is often referred to as an “alarmin” cytokine [17]. ST2, the specific ligand of IL-33, features a Toll-like receptor/interleukin-1 receptor (TLR/IL-1R) domain and belongs to the interleukin-1 receptor-like family (IL1RL1) [18,19]. Upon exposure to external stimuli, cells rapidly secrete IL-33 into the extracellular space. Acting as an endogenous damage-associated molecular pattern (DAMP), IL-33 binds to the ST2 receptor. This binding event results in the formation of a dimer complex, which then recruits IL-1RAcP. The assembled complex activates tumor necrosis factor receptor-associated factor 6 (TRAF6), thereby triggering the activation of downstream signaling pathways, prominently including the nuclear factor-κB (NF-κB) and mitogen activated protein kinase (MAPK) pathways, and ultimately leading to the initiation of relevant inflammatory and immune responses [20]. Immunomodulatory role of IL-33/ST2 pathway in COPD Recent studies have demonstrated that inflammatory immune responses in patients with COPD contribute to lung tissue damage through various mechanisms, such as oxidative stress and dysregulated inflammatory signaling [21,22]. These processes render the damaged lung tissue recognizable as self-antigens by autoreactive T cells, thereby initiating an inflammatory cascade that activates T cells. This cascade further recruits and activates macrophages, neutrophils, and natural killer cells, exacerbating pulmonary injury in COPD patients [5]. ST2 is a receptor primarily found in immune cells such as T cells, ILC2s, DCs and Macrophages, and it plays a vital role in this context. Upon cellular damage or stress, IL-33 is released and binds to ST2 on immune cells, triggering an inflammatory immune response [23]. This interaction promotes the release of pro-inflammatory mediators, such as cytokines and chemokines, leading to a persistent and detrimental immune response [[24], [25], [26]]. Consequently, the IL-33/ST2 signaling pathway is implicated as a key regulator of immune-mediated inflammation in COPD, highlighting its potential as a therapeutic target for mitigating disease progression (Fig. 2). T cells T cells play a pivotal role in the chronic inflammation, tissue damage, and immune regulation associated with COPD [27]. A study revealed that the number of CD8+ T cells in the sputum of COPD patients is significantly increased compared to both smokers and non-smokers with normal lung function in the control group [28]. These CD8+ T cells were found to be highly activated and exhibited elevated expression of perforin. Furthermore, the quantity of both CD4+ and CD8+ T cells in the airways of COPD patients was observed to increase in correlation with the progression of COPD severity when compared to smokers with normal lung function [29]. Additionally, research suggests that smoking may exacerbate the accumulation of T cells in the lung tissue, thereby enhancing their activation and maturation, which could predispose to a greater propensity for tissue damage [30]. Interestingly, in the bronchial mucosa of stable COPD patients, CD8+ T cells predominate among T cells. Research has reported that IL-33 activates CD8+ T cells via the ST2 receptor, enhancing their cytotoxic functions [31]. In COPD, this may contribute to airway epithelial cell damage and the amplification of inflammatory responses. Moreover, IL-33 promotes the infiltration of CD8+ T cells into lung tissue by inducing the expression of chemokines, thereby exacerbating local inflammation and tissue injury [32,33]. Consequently, the development of neutralizing antibodies or small-molecule inhibitors targeting the IL-33/ST2 interaction and the inhibition of inflammatory cytokine signaling pathways hold significant potential for controlling T cell-mediated immune-inflammatory responses in COPD patients. Group 2 innate lymphoid cells It has been reported that 20%-40% of patients with COPD exhibit a type 2 inflammatory phenotype. This phenotype is strongly linked to an increased risk of future exacerbations, especially in patients with a prior history of exacerbations, where it often predicts a higher exacerbation rate [34]. Group 2 innate lymphoid cells (ILC2s) are early initiators of airway inflammation and play a critical role in type 2 immune responses [35]. Studies have demonstrated that upon stimulation by allergens, viruses, or environmental pollutants, airway epithelial cells release cytokines such as IL-33, IL-25, and TSLP, which directly activate ILC2s. In turn, activated ILC2s secrete IL-5 and IL-13, recruiting eosinophils and mast cells to the airway and triggering robust inflammatory responses [36]. Mitogen-activated protein kinases (MAPKs) comprise multiple subtypes, including ERK, p38 MAPK, and JNK. As critical signaling pathways that transmit signals from the cell membrane to the nucleus, they can be activated by stimulation with cytokines, neurotransmitters, serine proteases, and oxidative stress, and play important roles in the inflammatory response in COPD [37]. Among the MAPK pathways, the p38 MAPK and JNK subtypes can be activated by cigarette smoke and inflammatory factors, stimulating the release of IL-8, TNF-α, IL-6, and other proinflammatory cytokines from alveolar epithelial cells and macrophages. This further recruits neutrophils, macrophages, and other inflammatory cells into the lung, thereby amplifying pulmonary inflammation [38,39]. In addition, abnormal activation of ERK in COPD may promote the excessive proliferation of airway epithelial cells and fibroblasts, contributing to airway wall thickening and fibrosis, which ultimately impairs lung function [40]. Notably, p38 MAPK is one of the key molecules regulating airway and pulmonary inflammation in COPD. Studies have demonstrated that p38 MAPK mediates IL-33-induced activation of ILC2s. It promotes the production of IL-6 and IL-13 via the downstream MK2/3 kinases and phosphorylates GATA-3, thereby driving ILC2s to secrete IL-5 and IL-13 [41]. These events induce the differentiation, chemotaxis, and secretory activity of eosinophils, further exacerbating inflammatory responses in COPD. Tregs Tregs are a subset of T cells with immunosuppressive functions, primarily maintaining immune homeostasis through the secretion of anti-inflammatory cytokines such as IL-10 and TGF-β, as well as by suppressing the activity of other immune cells [42]. Notably, researchers have reported a reduction in Tregs populations in the lungs of COPD patients compared to non-COPD smokers [43]. This loss of Tregs is believed to contribute to the persistent inflammation and dysregulated immune responses observed in COPD [44]. Furthermore, intracellular expression of FOXP3 is currently recognized as the most specific marker for human Tregs. Compared to smokers with normal lung function, stable COPD patients exhibit decreased levels of FOXP3 mRNA in sputum and a reduced number of Tregs in bronchoalveolar lavage (BAL) [45]. Tregs express the ST2 receptor, through which IL-33 can activate the PI3K/Akt and MAPK signaling pathways, thereby influencing Tregs proliferation, differentiation, and function [46]. In COPD, the reduction in Tregs numbers or impairment of their function may be associated with dysregulation of the IL-33/ST2 signaling pathway, contributing to uncontrolled inflammatory responses. Furthermore, IL-33 has been shown to potentially induce the conversion of Tregs into Th2-like cells, thereby compromising their immunosuppressive capabilities and promoting type 2 inflammatory responses and tissue damage [47]. Targeting the IL-33/ST2 pathway may represent a therapeutic strategy to restore the immunosuppressive function of Tregs, thereby mitigating inflammation in COPD. Additionally, such interventions could reduce Tregs exhaustion or their conversion into Th2-like cells, further protecting lung tissue from injury. Dendritic cells The regulatory effect of the IL-33/ST2 pathway on Dendritic cells (DCs) has increasingly attracted more attention. Some researchers have revealed that IL-33 can directly act on DCs via the ST2 receptor, promoting their activation and maturation [[48], [49], [50]]. This process induces DCs to highly express co-stimulatory molecules such as CD80, CD86, and MHC II, thereby enhancing their antigen-presenting ability [10,51]. Furthermore, activated DCs are capable of secreting various pro-inflammatory cytokines, such as IL-6, TNF-α, and IL-12, which further exacerbate the airway inflammatory response in COPD [52]. Additionally, DCs activated by IL-33 can promote the differentiation of T cells into Th2 cells, leading to the release of Th2-type cytokines, including IL-4, IL-5, and IL-13 [53,54]. Through the IL-33/ST2 pathway, DCs can stimulate the activation and proliferation of fibroblasts, resulting in the thickening and fibrosis of the airway wall [55], which may play a crucial role in COPD airway remodeling. Consequently, excessive activation of the IL-33/ST2 signaling pathway may lead to an over-exaggerated inflammatory response, as well as thickening and fibrosis of the airway wall, increasing the risk of acute exacerbation of COPD. Natural killer cells The IL-33/ST2 pathway has been shown to enhance the effector functions of Natural killer (NK) cells [56]. IL-33 binds to the ST2 receptor, activating NK cells and promoting the release of proinflammatory cytokines such as IFN-γ and TNF-α, thereby amplifying their cytolytic activity [57]. However, excessive activation of NK cells may result in chronic pulmonary tissue injury through the release of cytotoxic mediators such as granzymes and perforin, which may contribute to the deleterious effects observed in COPD associated airway inflammation [58]. Furthermore, studies have found that IL-33 enhances the cytotoxic potential of NK cells, enabling them to target damaged or infected airway epithelial cells [59]. In COPD, this mechanism may exacerbate the disruption of the airway epithelial barrier, accelerating disease progression. Consequently, pharmacological inhibition of the IL-33/ST2 could reduce NK cell-mediated hyperactivation and inflammatory responses, potentially alleviating pathological processes in COPD and protecting lung tissue from immune-mediated damage. In COPD, the populations of DCs subsets, Conventional type 1 dendritic cells (cDC1) and Conventional type 2 dendritic cells (cDC2), are increased and exhibit an activated phenotype [60]. In COPD, cDC1 primarily participates in antigen cross-presentation. It is capable of recognizing intracellular stimuli and activating CD8+ T cells responses, while also amplifying the immune functions of type 1 helper T cells and NK cells via IL-12, thereby mediating pulmonary inflammation and tissue injury. cDC2 drives chronic persistent inflammation and immune dysregulation by secreting pro-inflammatory cytokines and regulating CD4+ T cells differentiation. The synergistic crosstalk between cDC1 and cDC2 aggravates pulmonary inflammatory responses and accelerates lung tissue damage. Notably, lung cDCs derived from COPD patients can initiate and enhance the cytotoxicity of NK cells against lung epithelial cells. Furthermore, activated NK cells can promote DC maturation and the polarization of T cells toward inflammatory phenotypes such as Th17, while DCs, in turn, can activate and prime NK cells through cytokines such as IL-15 [61,62]. Conversely, Tregs can suppress the functions of both DCs and NK cells through various mechanisms, including cytokine production, cell-cell contact, and competition for growth factors like IL-2 [63,64]. Thus, a complex bidirectional interplay among DCs, NK cells, and Tregs may contribute to a self-perpetuating cycle of inflammation and lung tissue damage in COPD (Fig. 3).Fig. 3Interactions among DCs, NK Cells, and Tregs in the immune-inflammatory microenvironment of COPD. DCs activate NK cells by secreting cytokines such as IL-12 and IL-15, promoting NK cells survival. Additionally, DCs can induce Tregs to secrete IL-10 and TGF-β, thereby maintaining immune tolerance. NK cells have strong cytotoxic capabilities, allowing them to eliminate immature DCs and Tregs through the release of granzyme B. Under certain conditions, NK cells can also induce DCs maturation. Tregs mainly serve to suppress immune responses by either inhibiting the cytotoxicity of NK cells or by eliminating activated NK cells. Furthermore, Tregs can impair the antigen-presenting capacity of DCs, thereby modulating downstream DCs functions. These intricate interactions among DCs, NK cells, and Tregs significantly influence the immune-inflammatory microenvironment in COPD. Interactions among DCs, NK Cells, and Tregs in the immune-inflammatory microenvironment of COPD. DCs activate NK cells by secreting cytokines such as IL-12 and IL-15, promoting NK cells survival. Additionally, DCs can induce Tregs to secrete IL-10 and TGF-β, thereby maintaining immune tolerance. NK cells have strong cytotoxic capabilities, allowing them to eliminate immature DCs and Tregs through the release of granzyme B. Under certain conditions, NK cells can also induce DCs maturation. Tregs mainly serve to suppress immune responses by either inhibiting the cytotoxicity of NK cells or by eliminating activated NK cells. Furthermore, Tregs can impair the antigen-presenting capacity of DCs, thereby modulating downstream DCs functions. These intricate interactions among DCs, NK cells, and Tregs significantly influence the immune-inflammatory microenvironment in COPD. Macrophages The upregulation of CCL2 expression within lung tissues represents a characteristic feature of the inflammatory response in COPD. Accumulating evidence from research studies has indicated that by blocking the CCL2-CCR2 axis, the activation of Macrophages can be inhibited [65,66]. In turn, leads to a reduction in the secretion of cytokines such as MMP-9 and TGF-β, thereby alleviating lung injury in COPD patients [67]. Moreover, in comparison to smoker controls with normal lung function, as the severity of COPD advances, there is a notable increase in the number of Macrophages present in the small airways [68]. Accumulating evidence has unequivocally demonstrated that IL-33 drives the polarization of Macrophages towards the M1-type phenotype through interaction with the ST2 receptor [69,70]. This process is orchestrated by the activation of the NF-κB and MAPK signaling pathways, culminating in the copious release of pro-inflammatory cytokines. These cytokines, including IL-6, IL-8, TNF-α, and IL-1β, play central roles in orchestrating the inflammatory response and inflicting tissue damage [71,72]. Moreover, in the subset of COPD patients who develop the complication of pulmonary hypertension, the IL-33/ST2 pathway, acting through Macrophage-mediated inflammatory reactions, promotes the activation of pulmonary vascular endothelial cells and instigates vascular remodeling processes [73]. In summary, the IL-33/ST2 pathway exerts a pivotal influence on the inflammatory response, tissue remodeling, and pulmonary vascular pathologies associated with COPD by precisely regulating the functions of Macrophages. Target the IL-33/ST2 pathway IL-33, a tissue-derived nuclear cytokine, targets immune cells expressing the ST2 receptor and plays a significant role in the pathogenesis and progression of COPD. This observation highlights the therapeutic promise of targeting the IL-33/ST2 pathway to effectively treat COPD. By modulating this pathway, it may be possible to attenuate the inflammatory and immune responses driving COPD progression, thereby offering a novel strategy for disease management and improving patient outcomes [[74], [75], [76]]. Target IL-33 Currently, numerous IL-33 targeted antibody inhibitors are being investigated in clinical trials both domestically and internationally (Supplementary Table 1 and Supplementary Table 2). For example, Klaus et al. [77] reported the outcomes of a phase II clinical trial evaluating the efficacy of Itepekimab in treating COPD. The findings revealed that, in contrast to the placebo group, patients treated with Itepekimab experienced a significant reduction in acute exacerbations of COPD, highlighting the favorable therapeutic potential of this agent. Additionally, Tozorakimab, a novel therapeutic agent designed to inhibit IL-33, has been reported to possess a dual mechanism of action [78]. IL-33 exists in two forms: reduced IL-33 (IL-33red) and oxidized IL-33 (IL-33ox), which drive COPD through the ST2 pathway and the receptor for advanced glycation end products/epidermal growth factor receptor (RAGE/EGFR) pathway [73]. The former is associated with inflammation, while the latter is involved in epithelial remodeling and mucus secretion. Sam et al. compared the mechanistic differences between Tozorakimab and other monoclonal antibodies targeting IL-33 or ST2, and demonstrated that Tozorakimab promotes airway epithelial repair and reduces mucus secretion by inhibiting the biological effects mediated by the IL-33ox-RAGE/EGFR pathway in airway epithelial cells [79]. Tozorakimab exhibits a unique mechanism of action, which is distinct from that of Itepekimab and Astegolimab. In a phase I clinical trial conducted by Fred et al. [80], Tozorakimab can bind to endogenous IL-33 in serum and nasal airways, which significantly decreases serum IL-5 and IL-13 levels in patients with COPD and exhibits a good safety profile in comparison with placebo. Collectively, these findings strongly suggest that targeted inhibition of IL-33 holds great promise in significantly improving the serological parameters and clinical manifestations of COPD patients, offering a novel and potentially effective therapeutic strategy for this prevalent respiratory disease. Target ST2 Intriguingly, targeting ST2 represents a novel therapeutic strategy for COPD, which can not only modulate immunity and alleviate inflammation but also reduce the risk of acute exacerbations and improve pulmonary function, thereby conferring potential clinical benefits to patients with COPD [13]. Astegolimab, a humanized IgG2 monoclonal antibody, exerts its therapeutic effect by specifically targeting the ST2 receptor and thereby blocking the IL-33 pathway [81]. In a phase IIa clinical trial [82], the exacerbation rate at 48 weeks was not significantly different between the Astegolimab group and the placebo group, but in the prespecified analysis stratifying patients by blood eosinophil count, Astegolimab therapy achieved a superior reduction in exacerbation frequency in patients with low eosinophil levels (≤170 cells/μL) versus those with high eosinophil levels (>170 cells/μL). Moreover, it significantly improved the SGRQ-C score and enhanced FEV1 on secondary endpoints. Moreover, Astegolimab has been shown to possess an excellent safety profile. Furthermore, 9MW1911, another pharmaceutical agent designed to target the ST2 receptor, is currently in the phase I clinical trial stage. It is being investigated for its potential in the treatment of patients suffering from moderate to severe COPD, holding great promise for the development of novel therapeutic interventions in this area. Studies have demonstrated that ST2 inhibition therapy elicits therapeutic benefits in COPD patients with low eosinophil counts [82]. This is distinct from conventional biological agents, which predominantly target type 2 inflammatory pathways including IL-5 and IL-4Rα, and whose efficacy is largely dependent on an eosinophil-high phenotype [83,84]. Such divergence provides critical insights into dissecting the inherent heterogeneity of COPD. As the receptor for IL-33, ST2 inhibitors retain efficacy in patients with non-type 2 inflammation, supporting the notion that COPD represents a heterogeneous syndrome driven by diverse molecular mechanisms rather than a single pathological entity. These observations highlight the limitations of using eosinophils as the sole inflammatory stratification biomarker and substantiate that, in addition to type 2 inflammation, the IL-33/ST2 axis acts as a key driver of airway pathology in a distinct subset of COPD patients. The IL-33/ST2 pathway can be activated by multiple COPD related risk factors, such as cigarette smoke, oxidative stress, and epithelial damage, and contributes to epithelial barrier dysfunction, innate immune activation, neutrophilic inflammation, and airway remodeling, thereby exerting pivotal effects in both type 2 and non-type 2 inflammatory contexts [13]. Accordingly, precise patient stratification incorporating ST2, IL-33, and other pathway-associated biomarkers allows for the identification of subpopulations unresponsive to conventional biologics but potentially sensitive to ST2 inhibition. This approach not only broadens the scope of targeted therapeutic interventions for COPD but also deepens the mechanistic understanding of its heterogeneity, establishes a theoretical framework for molecular pathway-based precision medicine, and offers novel therapeutic promise for these patients. Conclusion As an important intercellular signaling pathway, IL-33/ST2 plays a significant role in the prevention, diagnosis, and treatment of COPD. Targeting IL-33 and ST2 can significantly improve the lung function of patients with moderate-severe and severe COPD and reduce the risk of disease exacerbation [20]. This indicates that targeting the IL-33/ST2 pathway has great potential value for the treatment of COPD. However, it is worth noting that the mechanism of action of the IL-33/ST2 pathway still requires further evaluation. For instance, it is essential to investigate the specific functions of IL-33/ST2 in various immune cells, such as Th2 cells, Macrophages, and NK cells, along with their networks of interaction. This exploration aims to uncover the specific mechanisms involved in the inflammatory remodeling of COPD and to further clarify the role of IL-33/ST2 in the treatment of pulmonary diseases. In addition, it is necessary to understand the responses of different immune cells to various pathogenic and environmental factors during the IL-33/ST2 blockade process, as well as the impact of alarmin release on current treatments. Notably, ongoing and innovative investigations into the targeting of the IL-33/ST2, including basic research, clinical trials, and studies on combination therapies, are essential to advance personalized and precision medicine for COPD. These efforts show promise in broadening treatment options and creating more effective strategies, ultimately enhancing outcomes for patients with COPD. Funding This study was supported by the Research and Development Project of 10.13039/501100010822Chengdu Science and Technology Bureau (2024-YF05-02542-SN); Research Project of Jianyang People's Hospital (JY202349). Clinical Scientific Research Fund project of 10.13039/100017520Chengdu Medical College in 2024 (24LHJGTY-01). CRediT authorship contribution statement Xiaoyan Xie: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing. Lei Yang: Conceptualization, Funding acquisition, Investigation, Methodology, Writing – original draft. Jie Chen: Data curation, Formal analysis, Investigation, Methodology. Yonghong Wu: Formal analysis, Investigation, Methodology. Jingjing Zhong: Formal analysis, Funding acquisition, Investigation. Hao Shen: Investigation, Methodology, Software. Gaofeng Zheng: Funding acquisition, Investigation, Methodology, Writing – review & editing. Declaration of competing interest The authors declare that they have no competing interests.